ALK and non-small cell lung carcinoma: Lin et al. reported on 94 advanced ALK(+) NSCLC patients and found that crizotinib had a better PFS in first-line use than in second-line use (median PFS 10.5 vs. 8.3 months, p = 0.020) (21).